AI Analysis | Feedback

• Think of it as an Intuitive Surgical (makers of the da Vinci robot), but focused on developing robotic systems for an even broader range of surgical specialties.
• Like a specialized, independent company building robotic surgical systems, similar to the dedicated robotics divisions within larger medical device companies like Medtronic or Stryker.

AI Analysis | Feedback

• Medical Surgical Devices: The company develops and manufactures various devices used in medical surgical procedures.
• Navigation and Control Technologies: They develop advanced technologies for navigation and control specifically designed for applications in medical robotics.

AI Analysis | Feedback

AI Analysis | Feedback

null

AI Analysis | Feedback

Dr. Sudhir Srivastava Founder, Chairman, and CEO

Dr. Sudhir Srivastava is a distinguished cardiac surgeon, renowned globally for his expertise in robotic cardiac surgery. He holds the record for performing the largest number of robotic cardiac procedures worldwide. In 2003, Dr. Srivastava co-founded Alliance Hospital LTD, a center specializing in cardiovascular disease, in Odessa, Texas, and served as its chairman for four years. He is the visionary behind SS Innovations' SSi Mantra, India's first indigenous surgical robotic system, aiming to make advanced surgical procedures affordable and accessible globally.

Milan Rao Global COO & CFO

Milan Rao was appointed Global Chief Operating Officer and Chief Financial Officer of SS Innovations International, Inc. in January 2026, a newly established role. He brings over 30 years of executive experience in both technology and healthcare industries, with a focus on operational efficiency, financial management, and growth strategies. Prior to joining SS Innovations, Mr. Rao held various senior leadership positions, including COO at Markets and Markets. He succeeded Naveen Kumar Amar, who resigned for personal reasons, and Dr. Vishwa Srivastava, who served as Interim CFO.

Dr. Vishwa Srivastava CEO - APAC

Dr. Vishwa Srivastava serves as the Chief Executive Officer for the Asia Pacific region at SS Innovations International. He has been actively involved in the field of robotic-assisted surgery since 2008. In 2009, while at St. Joseph's Hospital in Atlanta, he pioneered the development of a high-definition teaching website for robotic cardiac surgery. Dr. Vishwa Srivastava also served as the company's Interim Chief Financial Officer from July 2025 until September 2025.

Barry F. Cohen COO - Americas

Barry F. Cohen is the Chief Operating Officer of the Americas for SS Innovations International and also serves as the Chairman of the Board at Avra Medical Robotics Inc.. Mr. Cohen founded Avra Surgical, Inc., a medical technology company, between 2006 and 2008. He has served as Chief Executive Officer and a director of Avra Medical Robotics Inc. since February 2015. Earlier in his career, he was Director of Synalloy Corp. from approximately 1979 to 1983, and then its President from 1984 to 1985.

Avinash Kumar COO - India

Avinash Kumar is the Chief Operating Officer for SS Innovations in India. He is a seasoned executive with over 25 years of experience in the industry. His expertise includes managing manufacturing operations, vertical integrations, and medical product assemblies. Mr. Kumar's technical background is built on a Bachelor's degree in Mechanical Engineering and a 4-year engineering degree in Tool & Die Making.

AI Analysis | Feedback

The key risks to SS Innovations International (SSII) are:

1. Regulatory Risks for Global Expansion: SS Innovations International is actively pursuing regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and for the CE Mark in Europe, which are anticipated in late 2025 or early 2026. The company's expansion into these critical global markets is highly dependent on securing these approvals. Delays or failure to obtain these regulatory clearances pose a significant risk to its global growth strategy.
2. Financial Health and Need for Capital: Despite experiencing substantial revenue growth, SS Innovations International remains unprofitable, with a reported net loss of $12.13 million in 2025 and a net margin of -32.11%. The company is categorized as a "Speculative Growth" stock, and it has ongoing capital needs, with a "going concern warning" noted as a risk factor. While a private placement in March 2026 raised $18.6 million, the continuous need for capital to fund operations, research and development, and market expansion presents a risk, including potential dilution for existing shareholders.
3. Intense Competition: SS Innovations International operates in the highly competitive surgical robotics market, where it faces established players like Intuitive Surgical (developer of the da Vinci system). The company's ability to differentiate its SSi Mantra surgical robotic system and gain market share against entrenched competitors is crucial for its long-term success.

AI Analysis | Feedback

null

AI Analysis | Feedback

The primary product of SS Innovations International (symbol: SSII) is the SSi Mantra surgical robotic system, designed for a wide range of soft-tissue, robotically assisted surgeries. The company is strategically focused on the surgical robotics market, with a strong presence in India and plans for expansion into global markets, including the United States and Europe.

The addressable market for SS Innovations International's products falls within the broader global surgical robotics market, with a specific focus on the soft tissue surgery robot segment.

Estimates for the global surgical robotics market size vary across different reports:

• In 2024, the global surgical robots market was estimated at USD 4.31 billion and is projected to reach USD 9.60 billion by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 9.3% from 2025 to 2033.
• Another projection indicates the global robotic surgery market is expected to grow from USD 8.28 billion in 2025 to USD 16.40 billion by 2032, with a CAGR of 10.25%.
• Other reports value the global surgical robots market at USD 8.1 billion in 2024, with an anticipated growth to USD 38.4 billion in 2034, at a CAGR of 17.2% from 2025 to 2034.
• Further estimations place the global Surgical Robotic System Market size at USD 11,082.32 million in 2024, increasing to USD 29,785.13 million by 2032, with a CAGR of 13.21% from 2025 to 2032.
• The market was also valued at USD 8.24 billion in 2025 and is estimated to grow to USD 13.90 billion by 2031, with a CAGR of 8.96%.

Specifically for the **soft tissue surgery robot market**, which is a key area for SS Innovations International, the global market is projected to reach $773 million in 2025 and is expected to grow at a CAGR of 17.2% from 2025 to 2033.

Regionally, North America has been a significant market for surgical robotics, holding the largest revenue share of 50.90% in 2024 within the global surgical robots market. The U.S.-dominated surgical robotics market alone was estimated to be approximately $4.31 billion in 2024 and is predicted to reach $9.6 billion by 2033. Asia-Pacific is also anticipated to experience significant growth in this market.

AI Analysis | Feedback

1. Global Commercialization and Expansion of the SSi Mantra Surgical Robotic System: SS Innovations International is actively pursuing a global commercialization strategy for its flagship SSi Mantra surgical robotic system. The company has seen significant increases in SSi Mantra installations, with the cumulative installed base reaching 168 systems across ten countries as of December 31, 2025. This expansion into new global geographies is expected to drive substantial revenue growth, as the company aims to penetrate underserved markets.
2. Regulatory Approvals and Entry into Key Markets (U.S. and EU): A major driver for future revenue growth is the anticipated regulatory approvals in significant markets like the United States and the European Union. SS Innovations International expects the U.S. Food and Drug Administration (FDA) to finalize its review of the SSi Mantra by mid-2026. Concurrently, the company anticipates achieving European Union CE marking certification within the same year. Gaining access to these large, established markets will considerably broaden the company's addressable market and accelerate system installations and utilization.
3. Growth in Consumables, Instruments, and Services: As the installed base of SSi Mantra systems continues to grow globally, so will the demand for recurring revenue streams from associated consumables, instruments, and services. In 2025, revenue growth was largely driven by increased sales of SSi Mantra systems, instruments, and warranties. The company offers a comprehensive range of surgical instruments (SSi Mudra), accessory products, and essential services such as installation, repair, maintenance, and 24/7 technical support. The increasing utilization of the SSi Mantra system directly translates to higher sales of these high-margin complementary products and services.
4. Launch of New and Advanced Products: SS Innovations International continuously invests in developing new and advanced products to expand its offerings and address broader surgical needs. The company has developed new 5-millimeter surgical instruments specifically for specialties like pediatric and cardiac surgery, targeting large, underserved patient segments. Additionally, their product portfolio includes solutions like the NADI – Automated Coronary Anastomotic Connector, SSi Robotic Stapler, and advanced simulation and augmented reality tools (SSi Maya and SSi Holographic Anatomy), all of which can contribute to diversified revenue streams and market penetration.

AI Analysis | Feedback

Share Issuance

• On March 6, 2026, SS Innovations International completed a private placement, generating approximately $18.6 million in gross proceeds from the sale of 5,774,839 common shares.
• In February 2026, the company filed an S-1 registration statement for a $50 million share offering.
• Effective April 14, 2023, the company executed a one-for-ten reverse stock split and increased its authorized common stock to 250,000,000 shares in conjunction with the CardioVentures Merger.

Inbound Investments

• SS Innovations International completed an $18.6 million insider-led private placement on March 6, 2026.
• The company has raised $2.45 million in funding.

Capital Expenditures

• Capital expenditures for the last 12 months (as of March 15, 2026) totaled -$3.66 million.
• In Q4 2025, SS Innovations invested $1.7 million in capital expenditures, an increase of 127.1% from the prior quarter, to fund long-term assets and infrastructure.
• Expected capital expenditures for the upcoming year are focused on working capital, manufacturing expansion, clinical trials, and global marketing, funded in part by the recent $18.6 million private placement and a planned $50 million share offering.